All In Biotech

Drug Trial Radar · NCT07717905

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)

A Randomized, Double-Blind, Placebo-controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Adult Patients With Chronic Spontaneous Urticaria.

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jun 29, 2026

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Bambusa TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase IIa, randomized, blinded, placebo controlled,Multiple-Ascending Dose study of BBT001 in adult patients with Chronic Spontaneous Urticaria.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • BBT001Drug

    BBT001 will be administered

  • PlaceboDrug

    Placebo will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events following multiple administration of BBT001Time frame: - Up to Day 183 post first dose administration
  2. Number of participants with change in vital sign measurements following treatment administration.Time frame: Up to Day 183 post first dose administratio
  3. Number of participants with change in serum blood parameters.Time frame: Up to Day 183 post first dose administration
  4. Number of participants with change in physical examination following treatment administrationTime frame: Up to Day 183 post first dose administration
  5. Number of participants with change in 12-lead electrocardiogram (ECG) results measurements following treatment administration.Time frame: Up to Day 183 post first dose administration

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China · Not yet recruiting

  • Peking University People's Hospital, Beijing

    Beijing, Beijing Municipality, China · Recruiting

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Jingzhou Central Hospital

    Jinzhou, Hubei, China · Not yet recruiting

  • Wuxi Second People's Hospital,

    Wuxi, Jiangsu, China · Not yet recruiting

  • The Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Not yet recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Not yet recruiting

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.